Immunotherapy for keratinocyte cancers. Part II: Identification and management of cutaneous side effects of immunotherapy treatments.

Chang, Anne Lynn S; Zaba, Lisa; Kwong, Bernice Y

Chang, Anne Lynn S; Zaba, Lisa; Kwong, Bernice Y.

Afiliação

Chang ALS; Department of Dermatology, Stanford University School of Medicine, Redwood City, California. Electronic address: alschang@stanford.edu.
Zaba L; Department of Dermatology, Stanford University School of Medicine, Redwood City, California.
Kwong BY; Department of Dermatology, Stanford University School of Medicine, Redwood City, California.

J Am Acad Dermatol ; 88(6): 1243-1255, 2023 06.

Article em En | MEDLINE | ID: mdl-37268391

Assuntos

Melanoma; Neoplasias Cutâneas; Humanos; Melanoma/patologia; Neoplasias Cutâneas/tratamento farmacológico; Neoplasias Cutâneas/patologia; Inibidores de Checkpoint Imunológico/efeitos adversos; Estudos Prospectivos; Imunoterapia/efeitos adversos; Queratinócitos/patologia

Palavras-chave

T-VEC; basal cell carcinoma; biologic; cemiplimab; cutaneous toxicity; imiquimod; immune-related adverse events; immunotherapy; keratinocyte carcinoma; oncologic outcomes; pembrolizumab; programmed cell death 1; programmed death; rechallenge; squamous cell carcinoma; steroid-sparing; talimogene laherparepvec; toll-like receptor 7

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Melanoma Tipo de estudo: Diagnostic_studies / Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: J Am Acad Dermatol Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google